What Bio Products Laboratory does

Bio Products Laboratory (BPL) is a UK-based pharmaceutical company specializing in the manufacture and distribution of plasma-derived medicinal products, operating within the Kedrion Biopharma group following a 2022 merger. Its core technology centers on plasma fractionation and purification at the FDA-approved Elstree production facility in Hertfordshire — a 130,000 square meter site located 25 km north of London. BPL's marketed portfolio of nine core branded products includes coagulation factors (COAGADEX for hereditary Factor X deficiency, OPTIVATE for haemophilia A, REPLENINE-VF for haemophilia B), the albumin therapy ZENALB, the subcutaneous immunoglobulin SUBGAM, the anti-D immunoglobulin D-GAM, and hyperimmune immunoglobulins for hepatitis B, rabies, and tetanus prophylaxis. COAGADEX is described as the first and only approved treatment for the ultra-rare hereditary Factor X deficiency.

BPL operates inside an integrated plasma supply chain: 68 KEDPLASMA collection centers in the United States and 8 UNICAplasma centers in the Czech Republic feed the broader Kedrion group's 7 production facilities across 5 countries, producing 38 life-saving and life-enhancing products distributed to over 100 countries. BPL is the fifth-largest player globally in the plasma-derived sector. The company serves patients with rare and ultra-rare diseases (coagulation disorders, neurological disorders, immunodeficiencies, Rh sensitization) through healthcare providers and specialized pharmacists, with distribution executed via UK direct sales and international distributor networks supported by a 24/7 global customer service operation.

BPL generates revenue through one-time sales of its plasma-derived therapeutic products, with pricing handled through dedicated customer service channels rather than public disclosure. The company is a private limited company registered in England and Wales (No. 7343036) and is indirectly owned by funds advised by Permira, the private equity firm that acquired a controlling stake in Kedrion on 31 August 2022. Headcount across the integrated plasma collection and manufacturing operations is approximately 5,200 globally. BPL is subject to regulatory oversight by the MHRA (UK), the FDA (US), and the ABPI industry self-regulatory body.

Name

Bio Products Laboratory

Legal name

Bio Products Laboratory Limited

Website

https://bplgroup.com

Company type

Private

Founded year

1954

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bio Products Laboratory is a UK-based plasma fractionator producing nine core plasma-derived therapies (coagulation factors, albumin, immunoglobulins) at its FDA-approved Elstree facility, serving patients with rare and ultra-rare diseases across 100+ countries as part of the Kedrion Biopharma group.

Ownership category

akta.pro rank

Product category

Plasma-derived Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ), Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Plasma-Derived & Blood Products Distributors (HLAIAJAJ)

Keywords

• Plasma fractionation
• Plasma-derived therapies
• Coagulation factor concentrates
• Immunoglobulin products
• Albumin solutions

Headquarters

HQ city

Kingdom City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Plasma-derived Medicinal Product Sales: Sale of plasma-derived therapies including albumin-based therapies, immunoglobulins, and coagulation factors to treat rare and serious conditions. Products distributed in over 100 countries through direct sales and distributors.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Bio Products Laboratory (BPL) manufactures and distributes plasma-derived medicinal products for the treatment of rare and serious medical conditions. Its portfolio includes coagulation factors (human Factor X, Factor VIII, Factor IX), human albumin solutions, and standard and hyperimmune immunoglobulins used for replacement therapy, prophylaxis against infectious diseases, and prevention of Rh sensitisation. Products are produced at the FDA-approved Elstree facility and distributed globally.

Product overview

Bio Products Laboratory (BPL), now part of Kedrion Biopharma following a 2022 merger, is a plasma-derived therapeutics company producing life-enhancing and life-saving products. The portfolio consists of coagulation factors (COAGADEX for Factor X deficiency, OPTIVATE for Factor VIII/haemophilia A, REPLENINE-VF for Factor IX/haemophilia B), human albumin (ZENALB), standard immunoglobulins (SUBGAM for subcutaneous immunoglobulin replacement), and hyperimmune immunoglobulins (D-GAM for Rh disease, hepatitis B, rabies, and tetanus immunoglobulins). BPL operates the Elstree production facility (130,000 sqm, FDA-approved) alongside Kedrion's global network of 68 KEDPLASMA collection centers, 8 UNICAplasma centers, and 7 production facilities across 5 countries, distributing 38 products in over 100 countries.

Differentiator

Problem solved

Functional benefit

Brands

• COAGADEX: Human coagulation Factor X
• OPTIVATE
• REPLENINE-VF
• SUBGAM
• ZENALB
• D-GAM
• KEDPLASMA
• UNICAplasma

Products and services

• COAGADEX Human coagulation Factor X product used for the treatment of hereditary Factor X deficiency.
• OPTIVATE Human coagulation Factor VIII product used for the treatment of haemophilia A.
• REPLENINE-VF Human coagulation Factor IX product used for the treatment of haemophilia B.
• ZENALB Human Albumin solution used for plasma volume expansion and treatment of hypoalbuminaemia.
• SUBGAM Human normal subcutaneous Immunoglobulin 16% used for immunoglobulin replacement therapy.
• D-GAM Human Anti D Immunoglobulin used for prevention of Rh sensitisation in Rh-negative mothers.
• HUMAN HEPATITIS B IMMUNOGLOBULIN Hepatitis B Immunoglobulin for post-exposure prophylaxis against hepatitis B infection.
• HUMAN RABIES IMMUNOGLOBULIN Human Rabies Immunoglobulin for post-exposure prophylaxis against rabies infection.
• HUMAN TETANUS IMMUNOGLOBULIN Human Tetanus Immunoglobulin for prevention and treatment of tetanus.

Quantifiable outcome

• Rare hereditary deficiency treatment success rate: first and only approved treatment for condition affecting 1 in a1 million people

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• CSL Behring: CSL Behring is the global #1 plasma fractionator with the largest plasma collection network and a full portfolio (immunoglobulins, albumin, coagulation factors including Idelvion/Afstyla), directly comparable to BPL's full-spectrum plasma-derived offering and Kedrion-BPL's 5th-place global position.
• Grifols: Grifols is the world's #2 plasma fractionator with a vertically integrated network of >300 plasma centers producing albumin, Ig, Factor VIII, and alpha-1 antitrypsin; closely matches BPL/Kedrion's vertically integrated plasma-to-product model and competing in the same therapeutic categories.
• Takeda (Plasma-Derived Therapies): Takeda's PDT unit (inherited from Baxalta/Shire) is a top-tier plasma fractionator competing head-to-head with BPL/Kedrion in albumin, Ig (Gammagard), and coagulation factors (Advate, Adynovate, Feiba); highly comparable in scale and product breadth to the BPL-Kedrion combined franchise.

Direct peers

• Octapharma: Octapharma is one of the largest privately held plasma fractionators globally, producing immunoglobulins (Octagam, Gammanorm), coagulation factors (Nuwiq, Octanate), and albumin — a near-direct competitor to BPL's product mix and a fellow top-5 plasma player.
• Kedrion Biopharma: Kedrion is BPL's direct parent company and the operating group since the 2022 combination; Kedrion operates the KEDPLASMA and UNICAplasma collection networks (which BPL uses) and additional fractionation sites — BPL/Kedrion should be evaluated as a single integrated plasma franchise.
• Biotest: Biotest is a German plasma fractionator producing immunoglobulins (Intratect, Pentaglobin), coagulation factors, and albumin; a direct mid-tier competitor to BPL with overlapping product categories, particularly in specific/specific Ig niches.

Regional players

• LFB (Laboratoire Français du Fractionnement): LFB is a French state-linked plasma fractionator producing Ig, albumin, and coagulation factors (Factor 8/9/wWF), directly comparable to BPL's product mix though primarily serving French/European healthcare systems — overlapping therapeutic categories.
• Sanquin Plasma Products: Sanquin is the Dutch nonprofit blood/plasma products manufacturer producing immunoglobulins, albumin, and coagulation factors from Dutch volunteer-donor plasma — comparable product portfolio to BPL though anchored to the Netherlands/EU donor base.
• GC Biopharma (Green Cross): GC Biopharma is a Korean plasma fractionator with products (IVIG, albumin, vaccines) overlapping BPL's portfolio categories; serves as a regional-plasma competitor rather than directly head-to-head in Western markets but exercises similar scale economics in plasma fractionation.

Emerging players

• Kamada: Kamada is an Israeli specialty plasma-derived therapeutics company focused on hyperimmune Ig (Hep B, Rabies, Tetanus) and alpha-1 antitrypsin; competing in the same specific-Ig niches where BPL markets SUBGAM and its hyperimmune franchise (Hep B, Rabies, Tetanus Ig).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kedrion-uk

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio Products Laboratory